Search

Displaying results 4491 - 4500 of 10000 in total
  1. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

    Categories: Heterocyclic Compounds, 2-Ring
  2. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression.

  3. Drug

    Loteprednol etabonate

    go.drugbank.com/drugs/DB14596
    Approved

    It is used in ophthalmic solution for the treatment of steroid responsive inflammatory conditions of the eye such as allergic conjunctivitis, uveitis, acne rosacea, superficial punctate keratitis, herpes … Loteprednol Etabonate (LE) is a topical corticoid anti-inflammatory.

    Mixtures: TOBRALOT 5 MG+3 MG/ML GÖZ DAMLASI, SÜSPANSİYON, 1 ADET, LOTEMICIN®Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  4. Drug

    Sibrotuzumab

    go.drugbank.com/drugs/DB06474
    Investigational

    Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.

  5. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is being developed by Rinat and is currently in Phase I clinical trials. … RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain.

  6. Drug

    Zuretinol acetate

    go.drugbank.com/drugs/DB12112
    Investigational

    Zuretinol acetate has been used in trials studying the treatment of Impaired Dark Adaptation, RP (Retinitis Pigmentosa), Retinitis Pigmentosa (RP), and LCA (Leber Congenital Amaurosis).

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Ixabepilone

    go.drugbank.com/drugs/DB04845
    ApprovedInvestigational

    Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. … Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: Azaepothilone B, Aza-epothilone B
  8. Drug

    Bimakalim

    go.drugbank.com/drugs/DB19948
    Experimental

    Bimakalim is a small molecule drug. The usage of the INN stem '-kalim' in the name indicates that Bimakalim is a potassium channel activator, antihypertensive. … Bimakalim has a monoisotopic molecular weight of 278.11 Da.

    Categories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 1-Ring
  9. Drug

    Clenoliximab

    go.drugbank.com/drugs/DB06241
    Experimental

    Clenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.

  10. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

    Categories: Heterocyclic Compounds, 2-Ring